GlassScriptPhysician profile
John C Sciales
NPI 1942230362
$78,055.49
in general payments reported to CMS, 2019-2025
55 companies · $490 in 2025
The $490 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,613 · 2020: $7,159 · 2021: $22K · 2022: $17K · 2023: $25K · 2024: $289 · 2025: $490.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $20K · Food and Beverage: $4,047 · Travel and Lodging: $2,177.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $19,710.00 |
| Food and Beverage | $4,047.28 |
| Travel and Lodging | $2,177.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $30,518.40 | 2021-2023 | Vraylar, Qulipta |
| Alkermes, INC. | $14,835.39 | 2019-2025 | Lybalvi, Aristada, Aristada Initio |
| Supernus Pharmaceuticals, INC. | $10,300.12 | 2022-2023 | Qelbree |
| Allergan, INC. | $5,438.40 | 2019-2021 | |
| Neos Therapeutics, LP | $1,249.32 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $1,234.26 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,210.63 | 2020-2023 | |
| Amgen INC. | $1,161.61 | 2019-2025 | Repatha |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,071.26 | 2019-2023 | Trulance, Xifaxan |
| Astrazeneca Pharmaceuticals LP | $1,059.86 | 2019-2022 | |
| Novo Nordisk INC | $1,043.47 | 2019-2025 | Wegovy, Ozempic |
| Lilly USA, LLC | $1,001.28 | 2019-2022 | |
| Glaxosmithkline, LLC. | $799.19 | 2019-2022 | |
| Horizon Therapeutics Plc | $697.34 | 2019-2022 | |
| Pfizer INC. | $589.93 | 2019-2021 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Sciales listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.